We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-10 of 142

Virginia enacts first biosimilar substitution law
  • Shook Hardy & Bacon LLP
  • USA
  • April 4 2013

Virginia's governor has reportedly signed legislation (H.B. 1422S.B. 1285) that will allow the state's pharmacists to substitute biosimilars for

Virginia enacts the first state law regulating interchangeable biosimilar products
  • Duane Morris LLP
  • USA
  • March 28 2013

On March 16, 2013, Virginia became the first state to enact legislation regulating a pharmacist's substitution of an interchangeable biologic drug

Failure to test claims? Not in Virginia
  • Dechert LLP
  • USA
  • January 5 2011

We're sticking to a plain-vanilla report on a recent Virginia case because of our involvement in the Hormone Therapy litigation, but it is a good decision worth noting.

Court orders arbitration under “follow form” agreement to arbitrate in excess liability policy
  • Jorden Burt LLP
  • USA
  • December 1 2010

CB Fleet Company, Inc, a manufacturer of certain FDA-regulated over-the-counter medication, sued one of its excess liability carriers, Aspen Insurance UK Ltd.

Final court approval accorded to settlement of salmonella claims against bankrupt peanut co
  • Shook Hardy & Bacon LLP
  • USA
  • September 10 2010

According to a news source, a federal court in Virginia, adopting a magistrate judge's recommendation, has approved a $12 million settlement that will compensate those who became ill or died after consuming products containing Salmonella-contaminated peanuts.

Filing for patent term extension: every calendar day counts
  • McDermott Will & Emery
  • USA
  • April 28 2010

After a patent term extension (PTE) application for its anti-coagulant Angiomax patent was denied yet again by the U.S. Patent and Trademark Office (USPTO), The Medicines Company (MDCO) has, for the second time, challenged the USPTO’s decision by filing an Administrative Procedure Act (APA) lawsuit against the USPTO in the U.S. District Court for the Eastern District of Virginia.

A PMA device and a sales representative in the operating room - the breadth of Riegel preemption
  • Reed Smith LLP
  • USA
  • July 30 2008

A recent Virginia federal court decision demonstrates the powerful effect of the Riegel v. Medtronic precedent in product liability cases where PMA devices are subject to claims-sounding in negligence or breach of duty related to the design, manufacturing, and labeling of the device.